<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00759564</url>
  </required_header>
  <id_info>
    <org_study_id>A8811009</org_study_id>
    <secondary_id>2009-017796-20</secondary_id>
    <nct_id>NCT00759564</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function</brief_title>
  <official_title>An Open-label, 2-way Crossover Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Iv Cp-70429 And Oral Pf-03709270 In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate what effect renal dysfunction has on a drug that has an intravenous
      (CP-70,429) and an oral form (PF-03709270).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the pharmacokinetics and safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429. Cmax of CP-70429 following CP-70,429 intravenous dose was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-70429 Following CP-70,429 Intravenous Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-70429 Following CP-70,429 Intravenous Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of CP-70,429 Following CP-70,429 Intravenous Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) of CP-70429 Following CP-70,429 Intravenous Dose</measure>
    <time_frame>0 (pre-dose), 0 to 6, 6 to 12, 12 to 24 hours post-dose</time_frame>
    <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following PF-03709270 Oral Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429. Cmax of CP-70429 following CP-70,429 intravenous dose was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-70429 Following PF-03709270 Oral Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-70429 Following PF-03709270 Oral Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of CP-70429 Following PF-03709270 Oral Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) of CP-70429 Following PF-03709270 Oral Dose</measure>
    <time_frame>0 (pre-dose), 0 to 6, 6 to 12, 12 to 24 hours post-dose</time_frame>
    <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t1/2) of CP-70429 Following CP-70,429 Intravenous Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t1/2) of CP-70429 Following PF-03709270 Oral Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing given intravenous dose by AUC inf. AUC inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing the given oral dose by AUCinf. AUC inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Plasma Concentrations of CP-70429 Exceeding 0.5 Microgram Per Milliliter Following Intravenous Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 microgram per milliliter (mcg/mL) at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Plasma Concentrations of CP-70429 Exceeding 0.5 Microgram Per Milliliter Following PF-03709270 Oral Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Plasma Concentrations of CP-70429 Exceeding 1.0 Microgram Per Milliliter Following Intravenous Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 1.0 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 1.0 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Plasma Concentrations of CP-70429 Exceeding 1.0 Microgram Per Milliliter Following PF-03709270 Oral Dose</measure>
    <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of CP-70429 and PF-03709270 Metabolites</measure>
    <time_frame>0.5, 2, 4, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
    <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429 and metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration Versus Time Summary of 2-Ethylbutyric Acid</measure>
    <time_frame>1, 3, 8 hours post-dose</time_frame>
    <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration Versus Time Summary of Plasma Formate</measure>
    <time_frame>1, 3, 8 hours post-dose</time_frame>
    <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 7-10 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
    <description>Criteria for laboratory test abnormality: Hematology (hemoglobin, hematocrit, red blood corpuscles [RBC] count: less than [&lt;]0.8*lower limit of normal [LLN], platelets: &lt;0.5*LLN/greater than [&gt;]1.75*upper limit of normal [ULN], leukocytes: &lt;0.6*LLN or &gt;1.5*ULN, lymphocytes, total neutrophils: &lt;0.8*LLN or &gt;1.2*ULN, basophils, eosinophil, monocytes: &gt;1.2*ULN); Liver Function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;0.3*ULN, total protein, albumin: &lt;0.8*LLN or &gt;1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin: &gt;1.5*ULN; Renal Function (blood urea nitrogen, creatinine: &gt;1.3*ULN, uric acid: &gt;1.2*ULN); Electrolytes (sodium: &lt;0.95*LLN or &gt;1.05*ULN, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN or &gt;1.1*ULN; creatine kinase: &gt;2.0*ULN; glucose fasting: &lt;0.6*LLN or &gt;1.5*ULN, urine white blood corpuscles [WBC] and RBC: greater than or equal to (&gt;=) 6/High Power Field [HPF]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Sign Abnormalities</measure>
    <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
    <description>Criteria for vital signs abnormalities included supine/sitting pulse rate of &lt;40 beats per minute (bpm) or &gt;120 bpm, supine systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), &gt;=30 mmHg maximum increase and decrease from baseline in same posture, supine diastolic blood pressure (DBP) of &lt;50 mmHg, &gt;=20 mmHg maximum increase and decrease from baseline in same posture, heart rate &lt;=45 beats per minute (bpm) or &gt;=120 bpm or decrease/increase of &gt;=15 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
    <description>Criteria for abnormal ECG (12-lead) values were defined as: maximum PR interval &gt;=300 millisecond (msec) and maximum increase of &gt;=25 percent for baseline value of &gt;200 msec and &gt;=50% for baseline value of &lt;=200 msec for PR interval, QRS interval &gt;=200 msec; QT interval corrected using the Fridericia formula (QTcF) &gt;=500 msec or increase of &gt;45 msec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Physical Examinations</measure>
    <time_frame>Baseline, 7-10 days after the last dose of study drug</time_frame>
    <description>Physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems. The examination assessed the participants for any potential changes in physical status, as determined by the investigator. Any untoward findings identified on physical exams conducted after the administration of the first dose of study medication was captured as an adverse event.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>IV CP-70,429 and cross over to PF-03709270</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-70,429 and PF-03709270</intervention_name>
    <description>Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).</description>
    <arm_group_label>IV CP-70,429 and cross over to PF-03709270</arm_group_label>
    <other_name>CP-70,429 - sulopenem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet one of the following renal function categories:

          -  Normal renal function (CLcr &gt;80 mL/min).

          -  Mild renal impairment (CLcr &gt;50 and &lt;80 mL/min).

          -  Moderate renal impairment (CLcr &gt;30 and &lt;50 mL/min).

          -  Severe renal impairment (CLcr &lt;30 mL/min).

        Exclusion Criteria:

        Women who are pregnant or nursing or women who are of childbearing potential. History of
        clinically significant allergies, including seasonal allergies, and especially drug
        hypersensitivity including known allergies to components of the study drug formulation,
        penicillin, carbapenems and/or cephalosporin antibiotics (eg, amoxicillin,
        amoxicillin/clavulanate, ampicillin, cefadroxil, cephalexin, cefaclor and cefixime).

        Subjects should not have evidence of a history of the following:

          -  normal renal function: clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological or
             allergic disease.

          -  renal impairment: any clinically significant (hepatic, cardiac or pulmonary or
             subjects with acute nephritic syndrome) diseases (except diabetes). Stable co-morbid
             disease where it is unlikely that the disease and medication will alter the outcome of
             the study will be allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centurion Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8811009</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>December 11, 2015</results_first_submitted>
  <results_first_submitted_qc>December 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2016</results_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a fixed sequence design study (not a complete 2 way crossover) in parallel groups of participants with varying degrees of renal impairment, where all subjects received the intravenous formulation in first period and then received the oral formulation in second period.</recruitment_details>
      <pre_assignment_details>Participants were planned to receive CP-70,429 800 milligram (mg) in all reporting groups. For severe renal impairment group, CP-70,429 dose was decreased from 800 mg to 200 mg as per protocol amendment. Only 1 participant received 800 mg dose and was excluded from all descriptive and statistical analyses as per change in planned analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CP-70,429 (800 mg) + PF-03709270: Normal Renal Function</title>
          <description>Participants with normal renal function (defined by creatinine clearance [CLcr] greater than [&gt;] 80 milliliter per minute [mL/min]) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="P2">
          <title>CP-70,429 (800 mg) + PF-03709270: Mild Renal Impairment</title>
          <description>Participants with mild renal impairment (defined by CLcr &gt;50 and less than or equal to [&lt;=] 80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="P3">
          <title>CP-70,429 (800 mg) + PF-03709270: Moderate Renal Impairment</title>
          <description>Participants with moderate renal impairment (defined by CLcr greater than or equal to &gt;=30 and &lt;=50 mL/min) received a single dose of CP­-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="P4">
          <title>CP-70,429 (800 mg) + PF-03709270: Severe Renal Impairment</title>
          <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="P5">
          <title>CP-70,429 (200 mg) + PF-03709270: Severe Renal Impairment</title>
          <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-­70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF­-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention Period (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (at Least 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention Period (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-70,429 (800 mg) + PF-03709270: Normal Renal Impairment</title>
          <description>Participants with normal renal function (defined by creatinine clearance [CLcr] greater than [&gt;] 80 milliliter per minute [mL/min]) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="B2">
          <title>CP-70,429 (800 mg) + PF-03709270: Mild Renal Impairment</title>
          <description>Participants with mild renal impairment (defined by CLcr &gt;50 and less than or equal to [&lt;=] 80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="B3">
          <title>CP-70,429 (800 mg) + PF-03709270: Moderate Renal Impairment</title>
          <description>Participants with moderate renal impairment (defined by CLcr greater than or equal to &gt;=30 and &lt;=50 mL/min) received a single dose of CP­-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="B4">
          <title>CP-70,429 (800 mg) + PF-03709270: Severe Renal Impairment</title>
          <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="B5">
          <title>CP-70,429 (200 mg) + PF-03709270: Severe Renal Function</title>
          <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-­70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period followed by a single oral dose of PF­-03709270 1000 mg in second intervention period. A washout period of at least 14 days was maintained between each intervention period.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="3.2"/>
                    <measurement group_id="B2" value="60.6" spread="7.3"/>
                    <measurement group_id="B3" value="64.3" spread="15.7"/>
                    <measurement group_id="B4" value="55">Standard deviation was not calculated as single participant was analyzed.</measurement>
                    <measurement group_id="B5" value="69" spread="9.4"/>
                    <measurement group_id="B6" value="62.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose</title>
        <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429. Cmax of CP-70429 following CP-70,429 intravenous dose was reported.</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The pharmacokinetic (PK) parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose</title>
          <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429. Cmax of CP-70429 following CP-70,429 intravenous dose was reported.</description>
          <population>The pharmacokinetic (PK) parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17700" spread="1880.3"/>
                    <measurement group_id="O2" value="22070" spread="3420.8"/>
                    <measurement group_id="O3" value="28940" spread="6880.0"/>
                    <measurement group_id="O4" value="10340" spread="2784.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed Cmax for mild renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>124.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>106.57</ci_lower_limit>
            <ci_upper_limit>145.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed Cmax for moderate renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>163.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>139.72</ci_lower_limit>
            <ci_upper_limit>191.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed Cmax for severe renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>58.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.16</ci_lower_limit>
            <ci_upper_limit>70.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-70429 Following CP-70,429 Intravenous Dose</title>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-70429 Following CP-70,429 Intravenous Dose</title>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="11" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.50" spread="15" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O3" value="1.50" spread="23" lower_limit="1.50" upper_limit="1.50"/>
                    <measurement group_id="O4" value="1.50" spread="26" lower_limit="1.00" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-70429 Following CP-70,429 Intravenous Dose</title>
        <description>Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-70429 Following CP-70,429 Intravenous Dose</title>
          <description>Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31990" spread="4793.3"/>
                    <measurement group_id="O2" value="53610" spread="10520"/>
                    <measurement group_id="O3" value="78940" spread="23937"/>
                    <measurement group_id="O4" value="34270" spread="8430.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUClast for mild renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>167.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>137.27</ci_lower_limit>
            <ci_upper_limit>204.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUClast for moderate renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>246.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>202.11</ci_lower_limit>
            <ci_upper_limit>301.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUClast for severe renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>107.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.06</ci_lower_limit>
            <ci_upper_limit>130.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of CP-70,429 Following CP-70,429 Intravenous Dose</title>
        <description>AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of CP-70,429 Following CP-70,429 Intravenous Dose</title>
          <description>AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32160" spread="4775.5"/>
                    <measurement group_id="O2" value="54070" spread="10647"/>
                    <measurement group_id="O3" value="79870" spread="24619"/>
                    <measurement group_id="O4" value="35410" spread="9610.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUCinf for mild renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>168.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>137.40</ci_lower_limit>
            <ci_upper_limit>205.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUCinf for moderate renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>248.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>202.98</ci_lower_limit>
            <ci_upper_limit>303.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUCinf for severe renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>110.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.84</ci_lower_limit>
            <ci_upper_limit>134.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance (CLr) of CP-70429 Following CP-70,429 Intravenous Dose</title>
        <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).</description>
        <time_frame>0 (pre-dose), 0 to 6, 6 to 12, 12 to 24 hours post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) of CP-70429 Following CP-70,429 Intravenous Dose</title>
          <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.035" spread="5.578"/>
                    <measurement group_id="O2" value="6.936" spread="2.516"/>
                    <measurement group_id="O3" value="3.043" spread="3.297"/>
                    <measurement group_id="O4" value="2.303" spread="0.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following PF-03709270 Oral Dose</title>
        <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429. Cmax of CP-70429 following CP-70,429 intravenous dose was reported.</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The pharmacokinetic (PK) parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-­03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-­03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF-­03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-­03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following PF-03709270 Oral Dose</title>
          <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429. Cmax of CP-70429 following CP-70,429 intravenous dose was reported.</description>
          <population>The pharmacokinetic (PK) parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2747" spread="420.58"/>
                    <measurement group_id="O2" value="3704" spread="1053.3"/>
                    <measurement group_id="O3" value="6215" spread="1841.3"/>
                    <measurement group_id="O4" value="7830" spread="738.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed Cmax for mild renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>134.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>109.88</ci_lower_limit>
            <ci_upper_limit>165.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed Cmax for moderate renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>226.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>184.36</ci_lower_limit>
            <ci_upper_limit>277.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed Cmax for severe renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>285.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>221.80</ci_lower_limit>
            <ci_upper_limit>366.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-70429 Following PF-03709270 Oral Dose</title>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-­03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF­-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF-­03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF­-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-70429 Following PF-03709270 Oral Dose</title>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="11" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.50" spread="15" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.50" spread="23" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="2.50" spread="26" lower_limit="1.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-70429 Following PF-03709270 Oral Dose</title>
        <description>Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF­03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF­-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF­03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF-­03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-70429 Following PF-03709270 Oral Dose</title>
          <description>Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6403" spread="1355.9"/>
                    <measurement group_id="O2" value="13400" spread="4948.8"/>
                    <measurement group_id="O3" value="22600" spread="9034.3"/>
                    <measurement group_id="O4" value="47560" spread="15782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUClast for mild renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>209.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>158.81</ci_lower_limit>
            <ci_upper_limit>275.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUClast for moderate renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>353.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>267.83</ci_lower_limit>
            <ci_upper_limit>465.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUClast for severe renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>742.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>529.59</ci_lower_limit>
            <ci_upper_limit>1041.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of CP-70429 Following PF-03709270 Oral Dose</title>
        <description>AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-­03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF­-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF­-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of CP-70429 Following PF-03709270 Oral Dose</title>
          <description>AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6523" spread="1329.5"/>
                    <measurement group_id="O2" value="13670" spread="5088.1"/>
                    <measurement group_id="O3" value="23040" spread="9403.9"/>
                    <measurement group_id="O4" value="47990" spread="16191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUCinf for mild renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>209.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>158.72</ci_lower_limit>
            <ci_upper_limit>276.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUCinf for moderate renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>353.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>267.57</ci_lower_limit>
            <ci_upper_limit>466.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A one-way ANOVA model with group as a fixed effect was used to compare the natural log transformed AUCinf for severe renal impairment group (Test) to normal renal function group (Reference). The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Geometric Mean Ratio</param_type>
            <param_value>735.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>523.56</ci_lower_limit>
            <ci_upper_limit>1034.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance (CLr) of CP-70429 Following PF-03709270 Oral Dose</title>
        <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).</description>
        <time_frame>0 (pre-dose), 0 to 6, 6 to 12, 12 to 24 hours post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF­-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-­03709270: Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) of CP-70429 Following PF-03709270 Oral Dose</title>
          <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.47" spread="1.885"/>
                    <measurement group_id="O2" value="7.952" spread="2.537"/>
                    <measurement group_id="O3" value="4.239" spread="2.647"/>
                    <measurement group_id="O4" value="3.294" spread="4.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t1/2) of CP-70429 Following CP-70,429 Intravenous Dose</title>
        <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t1/2) of CP-70429 Following CP-70,429 Intravenous Dose</title>
          <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.034" spread="0.216"/>
                    <measurement group_id="O2" value="1.660" spread="0.586"/>
                    <measurement group_id="O3" value="1.823" spread="0.269"/>
                    <measurement group_id="O4" value="2.313" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t1/2) of CP-70429 Following PF-03709270 Oral Dose</title>
        <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF­-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-­03709270: Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t1/2) of CP-70429 Following PF-03709270 Oral Dose</title>
          <description>Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.837" spread="0.121"/>
                    <measurement group_id="O2" value="1.451" spread="0.335"/>
                    <measurement group_id="O3" value="1.809" spread="0.566"/>
                    <measurement group_id="O4" value="2.750" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL)</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing given intravenous dose by AUC inf. AUC inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL)</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing given intravenous dose by AUC inf. AUC inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.87" spread="3.9001"/>
                    <measurement group_id="O2" value="14.79" spread="2.6787"/>
                    <measurement group_id="O3" value="10.01" spread="3.7432"/>
                    <measurement group_id="O4" value="5.648" spread="1.2500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F)</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing the given oral dose by AUCinf. AUC inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F)</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing the given oral dose by AUCinf. AUC inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.5" spread="31.540"/>
                    <measurement group_id="O2" value="73.20" spread="24.115"/>
                    <measurement group_id="O3" value="43.38" spread="19.719"/>
                    <measurement group_id="O4" value="20.86" spread="6.8699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Plasma Concentrations of CP-70429 Exceeding 0.5 Microgram Per Milliliter Following Intravenous Dose</title>
        <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 microgram per milliliter (mcg/mL) at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Plasma Concentrations of CP-70429 Exceeding 0.5 Microgram Per Milliliter Following Intravenous Dose</title>
          <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 microgram per milliliter (mcg/mL) at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.310" spread="0.641" lower_limit="3.93" upper_limit="5.56"/>
                    <measurement group_id="O2" value="8.855" spread="1.542" lower_limit="6.23" upper_limit="11.1"/>
                    <measurement group_id="O3" value="11.40" spread="3.389" lower_limit="6.67" upper_limit="16.8"/>
                    <measurement group_id="O4" value="10.70" spread="4.009" lower_limit="6.65" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Plasma Concentrations of CP-70429 Exceeding 0.5 Microgram Per Milliliter Following PF-03709270 Oral Dose</title>
        <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF­-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-­03709270: Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Plasma Concentrations of CP-70429 Exceeding 0.5 Microgram Per Milliliter Following PF-03709270 Oral Dose</title>
          <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.915" spread="0.121" lower_limit="2.76" upper_limit="4.88"/>
                    <measurement group_id="O2" value="6.440" spread="0.335" lower_limit="5.03" upper_limit="10.9"/>
                    <measurement group_id="O3" value="8.185" spread="0.566" lower_limit="5.60" upper_limit="11.7"/>
                    <measurement group_id="O4" value="18.30" spread="0.832" lower_limit="9.48" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Plasma Concentrations of CP-70429 Exceeding 1.0 Microgram Per Milliliter Following Intravenous Dose</title>
        <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 1.0 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 1.0 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Plasma Concentrations of CP-70429 Exceeding 1.0 Microgram Per Milliliter Following Intravenous Dose</title>
          <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 1.0 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 1.0 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.935" spread="0.461" lower_limit="3.32" upper_limit="4.69"/>
                    <measurement group_id="O2" value="7.190" spread="0.849" lower_limit="5.50" upper_limit="7.88"/>
                    <measurement group_id="O3" value="9.240" spread="2.161" lower_limit="5.65" upper_limit="11.6"/>
                    <measurement group_id="O4" value="7.710" spread="2.304" lower_limit="5.52" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Plasma Concentrations of CP-70429 Exceeding 1.0 Microgram Per Milliliter Following PF-03709270 Oral Dose</title>
        <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
        <time_frame>0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF­-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF­-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-­03709270: Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-­03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Plasma Concentrations of CP-70429 Exceeding 1.0 Microgram Per Milliliter Following PF-03709270 Oral Dose</title>
          <description>Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile. If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.895" spread="0.121" lower_limit="1.95" upper_limit="3.42"/>
                    <measurement group_id="O2" value="4.990" spread="0.335" lower_limit="3.29" upper_limit="8.66"/>
                    <measurement group_id="O3" value="6.320" spread="0.566" lower_limit="4.47" upper_limit="9.72"/>
                    <measurement group_id="O4" value="12.15" spread="0.832" lower_limit="7.38" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of CP-70429 and PF-03709270 Metabolites</title>
        <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429 and metabolites.</description>
        <time_frame>0.5, 2, 4, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)</time_frame>
        <population>Data was not collected for this outcome because the metabolite data for CP-70,429 and PF-03709270 were not analyzed as per change in planned analysis</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of CP-70429 and PF-03709270 Metabolites</title>
          <description>PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429 and metabolites.</description>
          <population>Data was not collected for this outcome because the metabolite data for CP-70,429 and PF-03709270 were not analyzed as per change in planned analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration Versus Time Summary of 2-Ethylbutyric Acid</title>
        <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0.</description>
        <time_frame>1, 3, 8 hours post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration Versus Time Summary of 2-Ethylbutyric Acid</title>
          <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.38" spread="96.048"/>
                    <measurement group_id="O2" value="19.00" spread="53.740"/>
                    <measurement group_id="O3" value="15.25" spread="43.134"/>
                    <measurement group_id="O4" value="NA">No observations above the lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" spread="56.569"/>
                    <measurement group_id="O2" value="17.63" spread="49.851"/>
                    <measurement group_id="O3" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="NA">No observations above the lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="NA">No observations above the lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration Versus Time Summary of Plasma Formate</title>
        <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0.</description>
        <time_frame>1, 3, 8 hours post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O3">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O4">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration Versus Time Summary of Plasma Formate</title>
          <description>Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="NA">No observations above the lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="NA">No observations above the lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="NA">No observations above the lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="NA">No observations above the lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 7-10 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
        <population>Safety analysis set included all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (800 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single dose of CP-70,429 800 mg given as a 1.5-hour intravenous infusion under fasted condition in first intervention period.</description>
          </group>
          <group group_id="O5">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O6">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O7">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O8">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O9">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 7-10 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety analysis set included all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="0.216"/>
                    <measurement group_id="O2" value="5" spread="0.586"/>
                    <measurement group_id="O3" value="4" spread="0.269"/>
                    <measurement group_id="O4" value="0" spread="0.579"/>
                    <measurement group_id="O5" value="3" spread="0.121"/>
                    <measurement group_id="O6" value="6" spread="0.335"/>
                    <measurement group_id="O7" value="4" spread="0.566"/>
                    <measurement group_id="O8" value="6" spread="0.831"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Abnormalities</title>
        <description>Criteria for laboratory test abnormality: Hematology (hemoglobin, hematocrit, red blood corpuscles [RBC] count: less than [&lt;]0.8*lower limit of normal [LLN], platelets: &lt;0.5*LLN/greater than [&gt;]1.75*upper limit of normal [ULN], leukocytes: &lt;0.6*LLN or &gt;1.5*ULN, lymphocytes, total neutrophils: &lt;0.8*LLN or &gt;1.2*ULN, basophils, eosinophil, monocytes: &gt;1.2*ULN); Liver Function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;0.3*ULN, total protein, albumin: &lt;0.8*LLN or &gt;1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin: &gt;1.5*ULN; Renal Function (blood urea nitrogen, creatinine: &gt;1.3*ULN, uric acid: &gt;1.2*ULN); Electrolytes (sodium: &lt;0.95*LLN or &gt;1.05*ULN, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN or &gt;1.1*ULN; creatine kinase: &gt;2.0*ULN; glucose fasting: &lt;0.6*LLN or &gt;1.5*ULN, urine white blood corpuscles [WBC] and RBC: greater than or equal to (&gt;=) 6/High Power Field [HPF]).</description>
        <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
        <population>Safety analysis set included all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (800 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single dose of CP-70,429 800 mg given as a 1.5-hour intravenous infusion under fasted condition in first intervention period.</description>
          </group>
          <group group_id="O5">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O6">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O7">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O8">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O9">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities</title>
          <description>Criteria for laboratory test abnormality: Hematology (hemoglobin, hematocrit, red blood corpuscles [RBC] count: less than [&lt;]0.8*lower limit of normal [LLN], platelets: &lt;0.5*LLN/greater than [&gt;]1.75*upper limit of normal [ULN], leukocytes: &lt;0.6*LLN or &gt;1.5*ULN, lymphocytes, total neutrophils: &lt;0.8*LLN or &gt;1.2*ULN, basophils, eosinophil, monocytes: &gt;1.2*ULN); Liver Function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: &gt;0.3*ULN, total protein, albumin: &lt;0.8*LLN or &gt;1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin: &gt;1.5*ULN; Renal Function (blood urea nitrogen, creatinine: &gt;1.3*ULN, uric acid: &gt;1.2*ULN); Electrolytes (sodium: &lt;0.95*LLN or &gt;1.05*ULN, potassium, chloride, calcium, bicarbonate: &lt;0.9*LLN or &gt;1.1*ULN; creatine kinase: &gt;2.0*ULN; glucose fasting: &lt;0.6*LLN or &gt;1.5*ULN, urine white blood corpuscles [WBC] and RBC: greater than or equal to (&gt;=) 6/High Power Field [HPF]).</description>
          <population>Safety analysis set included all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vital Sign Abnormalities</title>
        <description>Criteria for vital signs abnormalities included supine/sitting pulse rate of &lt;40 beats per minute (bpm) or &gt;120 bpm, supine systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), &gt;=30 mmHg maximum increase and decrease from baseline in same posture, supine diastolic blood pressure (DBP) of &lt;50 mmHg, &gt;=20 mmHg maximum increase and decrease from baseline in same posture, heart rate &lt;=45 beats per minute (bpm) or &gt;=120 bpm or decrease/increase of &gt;=15 bpm.</description>
        <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
        <population>Safety analysis set included all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (800 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single dose of CP-70,429 800 mg given as a 1.5-hour intravenous infusion under fasted condition in first intervention period.</description>
          </group>
          <group group_id="O5">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O6">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O7">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O8">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O9">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Abnormalities</title>
          <description>Criteria for vital signs abnormalities included supine/sitting pulse rate of &lt;40 beats per minute (bpm) or &gt;120 bpm, supine systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), &gt;=30 mmHg maximum increase and decrease from baseline in same posture, supine diastolic blood pressure (DBP) of &lt;50 mmHg, &gt;=20 mmHg maximum increase and decrease from baseline in same posture, heart rate &lt;=45 beats per minute (bpm) or &gt;=120 bpm or decrease/increase of &gt;=15 bpm.</description>
          <population>Safety analysis set included all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities</title>
        <description>Criteria for abnormal ECG (12-lead) values were defined as: maximum PR interval &gt;=300 millisecond (msec) and maximum increase of &gt;=25 percent for baseline value of &gt;200 msec and &gt;=50% for baseline value of &lt;=200 msec for PR interval, QRS interval &gt;=200 msec; QT interval corrected using the Fridericia formula (QTcF) &gt;=500 msec or increase of &gt;45 msec.</description>
        <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
        <population>Safety analysis set included all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (800 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single dose of CP-70,429 800 mg given as a 1.5-hour intravenous infusion under fasted condition in first intervention period.</description>
          </group>
          <group group_id="O5">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O6">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O7">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O8">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O9">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities</title>
          <description>Criteria for abnormal ECG (12-lead) values were defined as: maximum PR interval &gt;=300 millisecond (msec) and maximum increase of &gt;=25 percent for baseline value of &gt;200 msec and &gt;=50% for baseline value of &lt;=200 msec for PR interval, QRS interval &gt;=200 msec; QT interval corrected using the Fridericia formula (QTcF) &gt;=500 msec or increase of &gt;45 msec.</description>
          <population>Safety analysis set included all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Physical Examinations</title>
        <description>Physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems. The examination assessed the participants for any potential changes in physical status, as determined by the investigator. Any untoward findings identified on physical exams conducted after the administration of the first dose of study medication was captured as an adverse event.</description>
        <time_frame>Baseline, 7-10 days after the last dose of study drug</time_frame>
        <population>Safety analysis set included all participants who received the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-70,429 (800 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O2">
            <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O3">
            <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O4">
            <title>CP-70,429 (800 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single dose of CP-70,429 800 mg given as a 1.5-hour intravenous infusion under fasted condition in first intervention period.</description>
          </group>
          <group group_id="O5">
            <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
          </group>
          <group group_id="O6">
            <title>PF-03709270 (1000 mg): Normal Renal Function</title>
            <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O7">
            <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
            <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O8">
            <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
            <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
          <group group_id="O9">
            <title>PF-03709270 (1000 mg): Severe Renal Impairment</title>
            <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in Physical Examinations</title>
          <description>Physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems. The examination assessed the participants for any potential changes in physical status, as determined by the investigator. Any untoward findings identified on physical exams conducted after the administration of the first dose of study medication was captured as an adverse event.</description>
          <population>Safety analysis set included all participants who received the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 7-10 days after the last dose of study drug (up to 32 days)</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-70,429 (800 mg): Normal Renal Function</title>
          <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
        </group>
        <group group_id="E2">
          <title>CP-70,429 (800 mg): Mild Renal Impairment</title>
          <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
        </group>
        <group group_id="E3">
          <title>CP-70,429 (800 mg): Moderate Renal Impairment</title>
          <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single dose of CP-70,429 800 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
        </group>
        <group group_id="E4">
          <title>CP-70,429 (800 mg): Severe Renal Impairment</title>
          <description>Participants with severe renal impairment received a single dose of CP-70,429 800 mg given as a 1.5-hour intravenous infusion under fasted condition in first intervention period.</description>
        </group>
        <group group_id="E5">
          <title>CP-70,429 (200 mg): Severe Renal Impairment</title>
          <description>Participants with severe renal impairment (defined by CLcr &lt;30 mL/min) received a single dose of CP-70,429 200 mg given as an intravenous infusion over 1.5 hours in first intervention period.</description>
        </group>
        <group group_id="E6">
          <title>PF-03709270 (1000 mg): Normal Renal Function</title>
          <description>Participants with normal renal function (defined by CLcr &gt;80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
        </group>
        <group group_id="E7">
          <title>PF-03709270 (1000 mg): Mild Renal Impairment</title>
          <description>Participants with mild renal impairment (defined by CLcr &gt;50 and &lt;=80 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
        </group>
        <group group_id="E8">
          <title>PF-03709270 (1000 mg): Moderate Renal Impairment</title>
          <description>Participants with moderate renal impairment (defined by CLcr &gt;=30 and &lt;=50 mL/min) received a single oral dose of PF-03709270 1000 mg tablet in second intervention period.</description>
        </group>
        <group group_id="E9">
          <title>PF-03709270 (1000 mg): Severe Renal</title>
          <description>Participants with severe renal impairment received a single oral dose of PF-03709270 1000 mg tablet under fasted condition in second intervention period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucous stools</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

